Literature DB >> 3378206

Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue.

C A O'Brian1, G M Housey, I B Weinstein.   

Abstract

We have previously demonstrated that tamoxifen and related triphenylethylene compounds are potent inhibitors of protein kinase C (PKC). The present study demonstrates that PKC binds specifically and reversibly to the antiestrogen N-didesmethyltamoxifen when the drug is coupled to CNBr-activated agarose through its primary amine, in the absence of lipid and other cofactors of the enzyme. PKC did not bind to 4-hydroxytamoxifen, which had been immobilized on epoxy-activated Sepharose through its hydroxyl moiety. This shows that the binding of PKC to immobilized N-didesmethyltamoxifen was not merely due to hydrophobic interactions, since N-didesmethyltamoxifen and 4-hydroxytamoxifen have nearly identical hydrophobicities. These results demonstrate that PKC has specific triphenylethylene-binding sites, which may mediate the inhibition of PKC activity by these antiestrogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378206

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Authors:  Stephanie J Byer; Jenell M Eckert; Nicole M Brossier; Buffie J Clodfelder-Miller; Amy N Turk; Andrew J Carroll; John C Kappes; Kurt R Zinn; Jeevan K Prasain; Steven L Carroll
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

2.  [Regression of retroperitoneal fibrosis by combination therapy with tamoxifen and steroids].

Authors:  J Allendorff; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 3.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

4.  New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERα and downregulating PI3K/Akt-PKCα leading to caspase-dependent apoptosis.

Authors:  A Arun; M I Ansari; P Popli; S Jaiswal; A K Mishra; A Dwivedi; K Hajela; R Konwar
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

5.  Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors:  Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

Review 6.  Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Authors:  Sarah Mikelman; Natalie Mardirossian; Margaret E Gnegy
Journal:  J Chem Neuroanat       Date:  2016-08-30       Impact factor: 3.052

7.  Tamoxifen inhibits acidification in cells independent of the estrogen receptor.

Authors:  N Altan; Y Chen; M Schindler; S M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 8.  Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.

Authors:  Rosilla F Bachmann; Robert J Schloesser; Todd D Gould; Husseini K Manji
Journal:  Mol Neurobiol       Date:  2005-10       Impact factor: 5.590

9.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 10.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.